Goldman Sachs Upgrades Cepheid and Myriad, Restarts Thermo Fisher Coverage | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Cepheid and Myriad Genetics and reinstated Thermo Fisher Scientific as the investment firm revised estimates on a number of life science tools and molecular diagnostics vendors.

In a research report, analyst Isaac Ro upgraded Cepheid to a Buy rating, Myriad to Neutral, and reinstated Thermo Fisher at a Buy rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.